American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 876-882 , December 2008

Flare-up Rates with Bimatoprost Therapy in Uveitic Glaucoma

,Accepted 18 August 2008.

References 

  1. Takahashi T, Ohtani S, Miyata K, et al. A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol. 2002;46:556–562
  2. De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879–884
  3. Moorthy RS, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361–394
  4. Heinz C, Koch JM, Heiligenhaus A. Transscleral diode laser cyclophotocoagulation as primary surgical treatment for secondary glaucoma in juvenile idiopathic arthritis: high failure rate after short-term follow-up. Br J Ophthalmol. 2006;90:737–740
  5. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use (Experience and incidence in a retrospective review of 94 patients). Ophthalmology. 1998;105:263–268
  6. Waheed K, Laganowski H. Bilateral poliosis and granulomatous anterior uveitis associated with latanoprost use and apparent hypotrichosis on its withdrawal. Eye. 2001;15:347–349
  7. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126:37–41
  8. Parentin F. Granulomatous anterior uveitis associated with bimatoprost (A case report). Ocul Immunol Inflamm. 2003;11:67–71
  9. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45:S337–S345[erratum] Surv Ophthalmol 2002;47:295
  10. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45:S347–S351
  11. Foster CS, Harper SL, Church LJ. Principles of diagnosis and therapy. In:  Foster CS,  Vitale AT editor. Diagnosis and Treatment of Uveitis. Philadelphia, Pennsylvania: W. B. Saunders; 2002;p. 79–103
  12. Cook JA, Geisel J, Halushka PV, Reines HD. Prostaglandins, thromboxanes, leukotrienes, and cytochrome P-450 metabolites of arachidonic acid. New Horiz. 1993;1:60–69
  13. Eakins K. Prostaglandin and non-prostaglandin mediated breakdown of blood-aqueous barrier. Exp Eye Res. 1977;25:483–498
  14. Yousufzai SY, Ye Z, Abdel-latif AA. Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and mammalian species. Exp Eye Res. 1996;63:305–310
  15. Kozawa O, Tokuda H, Miwa M, et al. Mechanism of prostaglandin E2-induced arachidonic acid release in osteoblast-like cells: independence from phosphoinositide hydrolysis. Prostaglandins Leukot Essent Fatty Acids. 1992;46:291–295
  16. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668–672
  17. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111:1658–1662
  18. Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419–4426
  19. Martin E, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. A 6-month assessment of bimatoprost vs timolol maleate: hypotensive efficacy, macular thickness and flare in ocular hypertensive and glaucoma patients. Eye. 2007;21:164–168
  20. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631–1634

PII: S0002-9394(08)00665-X

doi: 10.1016/j.ajo.2008.08.022

American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 876-882 , December 2008

Article Tools

* Image Usage & Resolution